Unravelling the Politics Behind India’s PM-JAY Health Insurance Scheme

By HEOR Staff Writer

July 26, 2023

The PM-JAY health insurance scheme, launched in India in 2018, was a crucial step towards universal health coverage (UHC). The policy’s design was shaped by a mix of technical and political elements, with a focus on bureaucratic aspects rather than ideological ones. The scheme was introduced by the ruling government just before national elections, leveraging policy legacies from previous and state insurance schemes. Key decisions such as the coverage amount and portability of benefits were centrally driven, while inputs from Indian states influenced features like the mode of implementation and provider network. This balanced approach facilitated the adoption of the reform. However, the scheme’s success hinges on addressing systemic issues and involving all stakeholders. As PM-JAY continues to be implemented, understanding the politics, power dynamics, and structural issues that shaped its formulation will be crucial.

Reference url

Recent Posts

Accelerating Biotechnology Patient Access in Europe Through Strategic Policy Reforms

By HEOR Staff Writer

May 1, 2026

The biotechnology patient access gap in Europe remains a critical challenge despite the continent’s scientific excellence. The EU Biotech Act offers a strategic opportunity to accelerate the delivery of advanced therapies — such as radioligand, cell and gene, and RNA-based treatments — from disco...
Insulin Substitution Portugal: Implications of Novo Nordisk’s Discontinuation
INFARMED has informed healthcare professionals about the upcoming discontinuation of several Novo Nordisk insulin products in Portugal and to provide clear guidance on insulin substitution Portugal. On 30 April 2026, INFARMED issued Circular 045/CD/100.20.200 announcing that Novo Nordisk Portu...
Dementia Pharmacotherapy Guidelines: Emphasizing Non-Pharmacological Approaches in Dutch Care
Dementia Pharmacotherapy Guidelines in the Netherlands continue to emphasize a primarily non-pharmacological approach to care. The revised Dutch pharmacotherapeutic consultation document highlights the modest clinical benefits of available drug treatments and assigns cholinesterase inhibitors (do...